CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 67 enrolled
Drug / intervention
Nicotine patch +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03521141
NCT03521141Phase 3Completed

Developing Precision Smoking Treatment in the Southern Community Cohort Study

Vanderbilt University Medical Center·interventional·Posted May 11, 2018·Updated Jun 1, 2020

In Brief

A Phase 3 clinical trial evaluating Nicotine patch, Varenicline, and 3 other interventions for Tobacco Use Cessation. Completed, enrolled 67 participants across 1 site.

Detailed Summary

Precision Care (PC) interventions, developed with guidance from a Community Advisory Board (CAB), will be piloted in a Randomized Clinical Trial (RCT) of approximately 100 eligible, consenting daily smokers in the Southern Community Cohort Study (SCCS) who are willing to make a quit attempt with medication and who reside in TN or MS. Participants will be randomized 1:1:1 to 1 of 3 groups; (1) group one informs selection of medication with information on nicotine metabolism; (2) group two offers a genetically-informed lung cancer risk score, and (3) group 3 is Guideline-Based Care (GBC). All groups will be followed for 6 months. All RCT participants will receive FDA-approved smoking cessation medication, be referred to the shared TN/MS state quitline, and be offered the NCI "Clearing the Air" standard intervention. The primary outcome is feasibility of delivering the precision interventions in the SCCS population, as evidenced by ability to recruit, engage, and retain participants through end of study. Secondary outcomes, for which the study is not powered, will include risk perceptions, use of quit aids, lung cancer screening among those who are eligible, and smoking cessation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 11, 2018
Enrollment StartMay 18, 2018
Primary CompletionApr 11, 2019
Study CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.1 years ago

Interventions

Nicotine patchdrug

FDA-approved smoking cessation pharmacotherapy

Vareniclinedrug

FDA-approved smoking cessation pharmacotherapy

Nicotine metabolismgenetic

Information on nicotine metabolism will be used to inform selection of medication.

Genetically-informed lung cancer risk scoregenetic

This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.

NCI "Clearing the Air"behavioral

A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.